Procalcitonin-Guided Antibiotic Therapy
Background: Procalcitonin and Its Role as a Biomarker of Bacterial Infections
Several serum biomarkers have been identified in recent years with potential uses to help diagnose local and systemic infections, differentiate bacterial and fungal infections from viral syndromes or noninfectious conditions, prognosticate, and ultimately guide management, particularly antibiotic therapy.
Currently, there are at least 178 serum biomarkers that have potential roles in managing patients with infections. Among these, procalcitonin is the most extensively studied biomarker.
Procalcitonin is the prohormone precursor of calcitonin that is expressed primarily in the C-cells of the thyroid gland and to a smaller extent in the neuroendocrine tissue of other organs, such as the lungs and intestines. The final step in the conversion of procalcitonin to calcitonin is inhibited by various cytokines and bacterial endotoxins and, therefore, high levels of cytokines and/or bacterial endotoxins cause procalcitonin levels to rise. Cytokines are released nonspecifically in response to inflammation and infection, but endotoxins are released specifically during bacterial infections because they are derived primarily from the Gram-negative bacterial cell wall. There is some evidence that procalcitonin is more specific for bacterial infections, with serum levels rising and falling more rapidly in bacterial infection.
The primary diagnostic utility of procalcitonin is thought to be in establishing the presence of local or systemic bacterial infections and in guiding their management.
Procalcitonin is often used with algorithms to guide care in association with clinical impressions.
- Soni NJ, Samson DJ, Galaydick JL, et al. Procalcitonin-Guided Antibiotic Therapy. Comparative Effectiveness Review No. 78 (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10058-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC124-EF. Available at www.effectivehealthcare.ahrq.gov/procalcitonin.cfm.
- Jones AE, Fiechtl JF, Brown MD, et al. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007 Jul;50(1):34- 41. PMID: 17161501.
- Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14(1):R15. PMID: 20144219.
- Tang H, Huang T, Jing J, et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009 Dec;37(6):497-507. PMID:19826761.
Your slide tray is being processed.